We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.

Delisted

AVEO was delisted on the 19th of January, 2023.

68 hedge funds and large institutions have $41.2M invested in AVEO Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 25 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

3% less funds holding

Funds holding: 7068 (-2)

31% less capital invested

Capital invested by funds: $59.9M → $41.2M (-$18.7M)

44% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 25

79% less call options, than puts

Call options by funds: $6K | Put options by funds: $28K

Holders
68
Holders Change
-2
Holders Change %
-2.86%
% of All Funds
1.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
15
Increased
14
Reduced
25
Closed
16
Calls
$6K
Puts
$28K
Net Calls
-$22K
Net Calls Change
-$22K
Name Holding Trade Value Shares
Change
Change in
Stake
BG
1
Baupost Group
Massachusetts
$5.72M
GPP
2
Great Point Partners
Connecticut
$4.29M -$240K -13,352 -4%
SCM
3
Sarissa Capital Management
Connecticut
$3.84M
BIT
4
BlackRock Institutional Trust
California
$3.76M -$2.2M -122,724 -33%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.29M +$401K +22,309 +17%
BFA
6
BlackRock Fund Advisors
California
$2.15M +$23.2K +1,289 +0.9%
PAI
7
Palo Alto Investors
California
$2.14M
Renaissance Technologies
8
Renaissance Technologies
New York
$1.91M -$42.4K -2,362 -2%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$1.66M +$326K +18,143 +20%
State Street
10
State Street
Massachusetts
$1.13M +$32.9K +1,831 +2%
DVC
11
Deer VI & Co
New York
$1.01M
GIM
12
Granahan Investment Management
Massachusetts
$1.01M +$362K +20,180 +43%
Northern Trust
13
Northern Trust
Illinois
$940K -$158K -8,792 -12%
GX
14
Greylock XI
Massachusetts
$876K
SM
15
Sabby Management
Florida
$857K -$1.65M -91,670 -62%
SCA
16
SAC Capital Advisors
Connecticut
$748K +$898K +50,000 New
Deutsche Bank
17
Deutsche Bank
Germany
$646K -$212K -11,783 -21%
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$475K -$129K -7,196 -18%
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$413K +$432K +24,050 +720%
DCM
20
DAFNA Capital Management
California
$391K +$470K +26,151 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$374K +$117K +6,519 +35%
TCIM
22
TIAA CREF Investment Management
New York
$369K
Bank of New York Mellon
23
Bank of New York Mellon
New York
$348K -$6.3K -351 -1%
Goldman Sachs
24
Goldman Sachs
New York
$329K -$43.2K -2,407 -10%
PPA
25
Parametric Portfolio Associates
Washington
$328K +$120K +6,684 +44%

AVEO Hedge Fund Activity: Q1 2014 in Review

68 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2014, worth a combined $41.2M — down 31% from $59.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AVEO and 15 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 14 added.

The largest buyer was SAC Capital Advisors, opening a new position worth an estimated $898K. The largest seller was MPM Asset Management, exiting entirely with an estimated $2.51M sold.

  • 68 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2014, down from 70 in Q4 2013.
  • Funds reported $41.2M of AVEO Pharmaceuticals, Inc. stock for Q1 2014, down 31% quarter-over-quarter.
  • 15 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2014 and 16 closed out, a net change of -1 holder.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2014 was SAC Capital Advisors, an estimated $898K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q1 2014 was MPM Asset Management, an estimated $2.51M sold.

Based on aggregated 13F filings for Q1 2014.